Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Ixempra

Roche Basel Switzerland

FDA approval for Roche diagnostic solid tumour test

Test will identify which patients could benefit from GSK immunotherapy.

- PMLiVE

EMA to evaluate Roche arthritis drug RoActemra for severe COVID-19

FDA approval has already been granted following positive phase 3 trials

Revolutionizing 3D Bioprinting & Disrupting the Drug Development Industry

Christine Whiteside, COO of VoxCell BioInnovation, discusses 3D bioprinting, including current and future applications and key barriers to realizing its full potential. She also shares her tips for getting new...

Impetus Digital

- PMLiVE

BMS’ Q2 results beat expectations with strong performance across core therapy areas

In Q2, BMS’ revenue came in at $11.7bn, a 16% increase on the same period last year

- PMLiVE

Roche engaged in talks with FDA for Alzheimer’s drug candidate

CEO Severin Schwan told reporters Roche will complete a phase 3 trial of gantenerumab in the second half of 2022

- PMLiVE

The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor

Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals how life...

Avalere Health

Webcast

Oncology landscape: How innovative market research methods can navigate you to success

Research Partnership

Building Better Patient Advocates Through Authentic Partnerships

Sabrina Hanna, Founder & CIO of the Cancer Collaborative, discusses precision medicine, innovation in oncology, how to build better patient advocates, and the current gaps when it comes to patient-centricity...

Impetus Digital

- PMLiVE

Roche’s gantenerumab improves biomarkers in inherited form of Alzheimer’s disease

However, anti-amyloid antibody did not show evidence of cognitive benefit for patients

- PMLiVE

BMS’s oral AML therapy Onureg receives EU approval

Onureg is the oral version of Vidaza, two of the drugs BMS gained as part of its acquisition of Celgene in 2019

- PMLiVE

BMS and Eisai to collaborate in deal worth up to $3.1bn

The two companies will work on developing a drug for endometrial, ovarian, lung and breast cancers

- PMLiVE

Regeneron’s COVID-19 drug boosts survival in hospitalised patients lacking antibodies

REGEN-COV reduced the risk of death among patients who did not have a natural antibody response

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links